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Abstract
Background: Diabetes is associated with increased cancer risk. The underlying mechanisms remain unclear. Hyperglycemia
might be one risk factor. HbA1c is an indicator of the blood glucose level over the latest 1 to 3 months. This study aimed to
investigate association between HbA1c level and cancer risks in patients with type 2 diabetes based on real life situations.
Methods: This is a cohort study on 25,476 patients with type 2 diabetes registered in the Swedish National Diabetes
Register from 1997–1999 and followed until 2009. Follow-up for cancer was accomplished through register linkage. We
calculated incidences of and hazard ratios (HR) for cancer in groups categorized by HbA1c #58 mmol/mol (7.5%) versus
.58 mmol/mol, by quartiles of HbA1c, and by HbA1c continuously at Cox regression, with covariance adjustment for age,
sex, diabetes duration, smoking and insulin treatment, or adjusting with a propensity score.
Results: Comparing HbA1c .58 mmol/mol with #58 mmol/mol, adjusted HR for all cancer was 1.02 [95% CI 0.95–1.10]
using baseline HbA1c, and 1.04 [95% CI 0.97–1.12] using updated mean HbA1c, and HRs were all non-significant for specific
cancers of gastrointestinal, kidney and urinary organs, respiratory organs, female genital organs, breast or prostate. Similarly,
no increased risks of all cancer or the specific types of cancer were found with higher quartiles of baseline or updated mean
HbA1c, compared to the lowest quartile. HR for all cancer was 1.01 [0.98–1.04] per 1%-unit increase in HbA1c used as
a continuous variable, with non-significant HRs also for the specific types of cancer per unit increase in HbA1c.
Conclusions: In this study there were no associations between HbA1c and risks for all cancers or specific types of cancer in
patients with type 2 diabetes.
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Introduction
Type 2 diabetes has been associated with increased risk of
several cancer types [1], such as breast cancer and gastrointestinal
cancer, and a decreased risk of prostate cancer has also been
found. The underlying mechanisms have been debated and
remain unclear [1,2]. A consensus statement from the societies of
diabetes and cancer researchers and experts has recently been
published [1,3]. This statement points out that there are
unanswered questions concerning the observed associations
between diabetes and cancer. We do not know the role of diabetes
itself or the typical metabolic disturbances in diabetes, or shared
risk factors of diabetes and cancer, or the diabetes medications in
relation to the observed links between cancer and diabetes [1–4].
Hyperglycemia, one of the main characteristics of diabetes, is
considered one possible reason for increased risk of cancer in
diabetes [5]. HbA1c is a test that measures the amount of glycated
hemoglobin in blood, and gives a stable estimate of blood glucose
control over the last 1 to 3 months [6].
More intensive glucose control in patients with type 2 diabetes
did not affect the risk of cancer incidence [7] or mortality [7,8] in
two randomized trials with mean of 3.5 or 5 years of follow-up.
Similar results were shown in a meta-analysis of major trials [9].
Inconsistent results were reported from previous observational
studies on the relationship between HbA1c levels and cancer
incidence or mortality, for reasons of different study cohorts, i.e.,
‘apparently healthy people’, mixed group of people with or
without diabetes, or patients without aclearly defined type of
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tion-based observational study based on Swedish patient registers
to assess the associations between HbA1c and incidence of all
cancers or cancers of specific types in patients with type 2 diabetes.
Methods
This is a prospective cohort study based on Swedish Registers:
the National Diabetes Register, the Cancer Register and the
Causes of Death Register. More details about these registers have
been described in a previous publication [14]. The study cohort,
all patients with type 2 diabetes, was selected from the Swedish
National Diabetes Register, with baseline years 1997–1999. The
cohort selected for the current study is based upon registry entries
in the Swedish National Diabetes Register from 1997–1999, which
are completely different from those used for the study on insulin
glargine and cancer risk, where the cohort was selected based on
registry entries in the Swedish Prescribed Drug Register in 2005
[14]. Outcomes during follow-up of the study cohort were
obtained through linkage to the Cancer Register and the Causes
of Death Register, with use of the Swedish personal identity
number, a unique identifier assigned to every resident in Sweden
and allowing linkage between different registers [14]. Figure 1
presents the compilation of the study cohort in the form of a flow
chart.
Study Cohort
The study cohort consisted of 25,476 type 2 diabetes patients
aged 25–90 years, with baseline data in 1997–1999 available for
all analyzed variables. All included patients have agreed by
informed consent to register in the NDR before inclusion. The
definition of type 2 diabetes is treatment with diet only, oral
hypoglycaemic agents only, or onset age of diabetes .40 years
combined with insulin only or insulin and oral agents. Exclusion
criteria were diagnosis of cancer of study interest or death before
the start of follow-up, as obtained through linkage to the Cancer
Register and the Causes of Death Register.
Exposure
HbA1c analyzes were quality assured nationwide by regular
calibration with the HPLC Mono-S method, and HbA1c values
were converted to the DCCT standard using the formula: HbA1c
(DCCT) =0.9236HbA1c (Mono-S) +1.345; R2=0.998 [15].
HbA1c was measured at baseline. HbA1c was also measured over
the follow-up period as an updated mean of annual measurements,
with the last observation carried forward for missing data. HbA1c
values were used annually until an event, or until censor date in
case of no event.
Follow-up
Cohort members were followed from the first day of the year
after the baseline clinical examinations in 1997–1999 until the first
diagnosis of outcome, or death, or the end of follow-up, December
31, 2009.
Outcomes
Study outcomes were the first diagnosis of any malignant cancer
(all cancer), or the first diagnosis of a specific type of malignant
cancer during follow-up. The outcomes were identified from the
Cancer Register using ICD coding. First incident all cancer was
defined as ICD-10 codes (C00–C97, D00–D09, D37–D48) (In-
ternational Classification of Diseases, 10th revision), and the
following specific types of cancer were also investigated: first
incident gastrointestinal cancer (ICD-10 code C15–C25), first
incident breast cancer in women (C50), and first incident prostate
cancer in men (C61). For cancer of specific sites, we included only
tumors that were histopathologically classified as adenocarcinoma
(WHO/HS/CANC/24.1 histology code 096). We also investigated
first incident cancer of kidney and urinary organs (C64–C68),
respiratory organs (C30–C39) and female genital organs (C51–
C58).
Potential Confounding Factors
Age, sex, diabetes duration, baseline body mass index [BMI
(kg/m
2)], smoking and insulin treatment were regarded as
potential confounding factors. BMI was calculated as weight
divided by height squared. A smoker was defined as a patient who
smoked one or more cigarettes per day, or who smoked tobacco
using a pipe, or who had stopped smoking within the past three
months.
Statistical Methods
The cohort was divided according to its median HbA1c value
into two groups of baseline, HbA1c #58 mmol/mol (7.5%) or
.58 mmol/mol, and into two groups of updated mean, HbA1c
#58 mmol/mol or .58 mmol/mol. Baseline characteristics are
presented in Table 1 as mean values with one standard deviation
(SD) and frequencies (%) in each group of baseline or updated
mean HbA1c #58 mmol/mol, or baseline or updated mean
HbA1c .58 mmol/mol. Significance test between the groups
were conducted with student’s t-test for means and X
2 test for
proportions. A propensity score was calculated for each participant
using forward logistic regression [16], including all baseline
covariables. Participants were divided into 5 strata based on
quintiles of the propensity score. General linear modeling (GLM)
was used to test the significance levels for the covariables between
the study groups after adjustment for the quintiles of the
propensity score (Table 1). Numbers and crude incidence rates
per 1,000 person-years of outcomes by groups of HbA1c
#58 mmol/mol or .58 mmol/mol are given in Table 2.
Cox proportional hazard regression was used to estimate hazard
ratios (HRs) with 95% confidence intervals (CI) for outcomes
(Tables 3, 4 and 5). The follow-up time was used as the time scale
[17]. The updated mean HbA1c value was treated as a strictly
time-dependent variable in the Cox regression to evaluate
glycemic exposure during follow-up, allowing for the use of
a recent value of updated mean HbA1c at each specific time point
in the modeling process. We used three different models for
adjustment when comparing groups with HbA1c #58 or
.58 mmol/mol (Table 3). Model 1 estimated crude hazard
ratios. Model 2 adjusted for age, sex (except in sex-specific
cancers), diabetes duration, smoking, and insulin treatment as
covariates. Model 3 used stratification with quintiles of a propensity
score including the same covariates as in Model 2. In addition, we
estimated HR for outcomes with higher quartiles of baseline or
updated mean HbA1c and the lowest quartile as reference,
adjusting for covariates according to Model 2 (Tables 4–5). Finally,
HR were estimated for outcomes per one %-unit increase in
baseline HbA1c as continuous variable, adjusting according to
Model 2 (Table 3). A Cox regression model was also used to
estimate 12-year incidence rate of outcomes, in which model
output was the 12-year rate for each participant, adjusted for
covariates as given in model 2 (Figure 2).
Proportional hazard assumption was tested with the Kolmo-
gorov-type supremum test using re-sampling, and introducing the
test of all time-dependent covariables simultaneously. Violations
of the proportional hazards assumption were detected for age in
the analysis of any type of cancer or prostate cancer, and this
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Table 1. Baseline characteristics in people with type 2 diabetes aged 25–90 years, by HbA1c #58 mmol/mol (#7.5%) or
.58 mmol/mol (.7.5%).
Baseline HbA1c Updated mean HbA1c
#58
(#7.5%)
.58
(.7.5%)
P
value
#
P
value
*
#58
(#7.5%)
.58
(.7.5%)
P
value
#
P
value
*
Number 12550 12926 – – 12478 12998 – –
HbA1c, % 6.9 (0.5) 8.5 (0.8) – – 6.7 (0.5) 8.5 (0.9) – –
Age, year 66.4 (12.0) 65.7 (11.1) ,0.001 0.175 66.8 (11.7) 65.3 (11.4) ,0.001 0.471
Men, N (%) 7167 (57.1) 7092 (54.9) ,0.001 0.634 7075 (56.7) 7184 (55.3) 0.022 0.447
Duration, year 7.2 (7.0) 10.8 (7.7) ,0.001 0.005 7.4 (7.1) 10.5 (7.7) ,0.001 0.059
BMI, kg/m
2 28.2 (4.7) 28.6 (4.9) ,0.001 0.989 28.2 (4.7) 28.7 (4.9) ,0.001 0.466
Smokers, N (%) 1540 (12.3) 1800 (13.9) ,0.001 0.557 1482 (11.9) 1858 (14.3) ,0.001 0.804
Insulin, N (%) 3424 (27.3) 7177 (55.5) ,0.001 0.001 3382 (27.1) 7219 (55.5) ,0.001 ,0.001
Data are given as means (SD) or numbers (frequencies %).
# without propensity score * with stratification by quintiles of propensity score.
doi:10.1371/journal.pone.0038784.t001
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age) in the Cox regression models. Similarly, violations were
detected for BMI in the analysis of cancer of respiratory organs,
and BMI quartiles were included in the model as a strata
variable. In addition, we analyzed adjusted hazard ratios for
incidence of all cancer and specific cancers by quartiles of
baseline HbA1c values, as well as by quartiles of updated mean
HbA1c values, using the lowest quartile 1 as reference (Tables 4–
5). Interactions between HbA1c categories and all covariables
were analyzed with maximum likelihood estimation, with no
interaction detected. All statistical analyzes were performed using
SAS (SAS Institute, US).
Ethics
The data linking of national registers required for this study was
approved by the Regional Ethics Review Board at the University
of Gothenburg. All data analyzed were anonymous; therefore,
informed consent for each individual was neither necessary
according to Swedish legislation act 2003:460 concerning research
on humans, nor is it possible when data is anonymous.
Table 2. Numbers and incidence rates of outcomes in people with type 2 diabetes aged 25–90 years, by HbA1c #58 mmol/mol
(#7.5%) or .58 mmol/mol (.7.5%).
Baseline HbA1c Updated mean HbA1c
All patients #58 mmol/mol .58 mmol/mol #58 mmol/mol .58 mmol/mol
N Incidence N Incidence N Incidence N Incidence N Incidence
All cancer 3433 15.73 1727 15.95 1706 15.52 1731 16.10 1702 15.38
Gastrointestinal cancer 826 3.42 415 3.45 411 3.38 405 3.38 421 3.45
Kidney and urinary cancer 86 0.35 46 0.38 40 0.32 50 0.41 36 0.29
Respiratory cancer 86 0.35 46 0.38 40 0.32 43 0.35 43 0.35
Female genital cancer 183 1.67 86 1.64 97 1.73 82 1.55 101 1.82
Breast cancer 309 2.89 143 2.77 166 3.00 143 2.74 166 3.03
Prostate cancer 740 5.70 391 5.94 349 5.46 403 6.21 337 5.20
N: Number of outcomes. Incidence rate: numbers/1,000 person-years.
doi:10.1371/journal.pone.0038784.t002
Table 3. Hazard ratios (HR) and 95% confidence intervals (95% CI) ) for all cancer and specific cancers by baseline or updated
mean HbA1c at Cox regression, in people with and type 2 diabetes followed for 12 years from 1997–99 to 2009.
Baseline HbA1c Baseline HbA1c (mmol/mol) Updated mean HbA1c (mmol/mol)
Per 1% #58 .58 #58 .58
increase Model 1 Model 2 Model 3 Model 1 Model 2 Model 3
HR (95% CI) HR (95% CI) HR (95% CI)
All cancer 1.01
(0.98–1.04)
Ref 0.99
(0.92–1.06)
1.02
(0.95–
1.10)
1.02
(0.95–
1.09)
Ref 1.01
(0.95–
1.08)
1.04
(0.97–
1.12)
1.03
(0.96–
1.10)
Gastrointestinal
cancer
1.00
(0.94–1.06)
Ref 0.98
(0.86–
1.12)
1.03
(0.89–
1.20)
1.02
(0.88–
1.18)
Ref 1.02
(0.89–
1.17)
1.12
(0.97–
1.29)
1.09
(0.94–
1.26)
Kidney and
urinary cancer
1.00
(0.94–1.06)
Ref 0.86
(0.56–
1.32)
0.86
(0.55–
1.36)
0.87
(0.55–
1.37)
Ref 0.71
(0.46–
1.09)
0.70
(0.44–
1.10)
0.70
(0.44–
1.10)
Respiratory
cancer
1.00
(0.85–1.19)
Ref 0.87
(0.57–
1.32)
0.83
(0.53–
1.31)
0.84
(0.53–
1.32)
Ref 0.99
(0.65–
1.52)
1.00
(0.64–
1.57)
1.00
(0.63–
1.56)
Female genital
cancer
1.00
(0.89–1.12)
Ref 1.06
(0.79–
1.41)
1.03
(0.75–
1.41)
1.06
(0.77–
1.46)
Ref 1.17
(0.88–
1.57)
1.18
(0.86–
1.61)
1.22
(0.89–
1.68)
Breast cancer 1.01
(0.92–1.10)
Ref 1.08
(0.87–
1.36)
1.08
(0.85–
1.38)
1.09
(0.86–
1.39)
Ref 1.10
(0.88–
1.38)
1.12
(0.88–
1.43)
1.12
(0.88–
1.43)
Prostate cancer 1.00
(0.94–1.06)
Ref 0.97
(0.84–
1.12)
1.04
(0.89–
1.21)
1.05
(0.90–
1.22)
Ref 0.92
(0.80–
1.07)
0.98
(0.84–
1.14)
0.96
(0.82–
1.11)
Model 1: Crude HR, without adjustment for covariates. Model 2: Adjustment for age, sex, diabetes duration, BMI, smoking, and insulin treatment as covariates. Model 3:
Adjusted HR after stratification with a propensity score. Adjustment by stratification with quintiles of a propensity score including covariates as in Model 2.
doi:10.1371/journal.pone.0038784.t003
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The study cohort was divided into two groups by the baseline
HbA1c value 58 mmol/mol (7.5%), and into two groups by the
updated mean HbA1c value 58 mmol/mol. The baseline char-
acteristics of each group are given in Table 1.
Mean HbA1c was 6.6% and 8.4% in the groups with baseline
HbA1c#58 mmol/mol and .58 mmol/mol, and 6.7% and 8.5%
in the groups with updated mean HbA1c #58 mmol/mol and
.58 mmol/mol, respectively. The group with higher baseline
HbA1c was significantly younger, had fewer men, longer diabetes
duration, higher BMI, more smokers, and was more often treated
with insulin at the start of follow-up. Similar differences were
observed regarding the groups based on higher versus lower
updated mean HbA1c. After stratification by quintiles of a pro-
pensity score, there were no significant differences in mean age,
diabetes duration, and all differences except the insulin treatment
disappeared.
Table 2 showed the numbers and incidence rates of incident
cancers in total and by subgroups of baseline or mean updated
HbA1c #58 mmol/mol and .58 mmol/mol. In total, we
observed 3,433 cancers in the cohort, yielding an incidence rate
of 15.73/1,000 person-years.
Table 3 presents HR for risk of cancer with patient groups of
HbA1c .58 mmol/mol versus those with #58 mmol/mol, using
three different models. There were no significant differences in
risks of any cancer or specific cancer in groups of baseline
HbA1c.58 mmol/mol compared to #58 mmol/mol, or in
groups of updated mean HbA1c.58 mmol/mol compared to
#58 mmol/mol.
Table 3 also shows HR for risk of cancer by one per cent unit
increase in baseline HbA1c as a continuous variable. These HR
were all non-significant for all cancer or cancer of specific types.
Figures 2 A–G presents complementary splines of 12-year
incidence rates of all cancer and cancer of specific types across
the range of baseline HbA1c at a Cox model with adjustment as in
Table 3.
In our additional analysis, we calculated adjusted hazard
ratios for incidence of all cancer and specific cancers when we
divided the cohort by quartiles of the baseline HbA1c values.
The 25
th,5 0
th and 75
th percentiles of baseline HbA1c were 50
mmmol/mol (6.7%), 58 mmol/mol (7.5%) and 69 mmol/mol
(8.5%). With the lowest quartile 1 as reference, no significant
differences in risk of all cancer or cancer of gastrointestinal,
prostate, breast or female genital organs were found in the
higher quartiles 2–4 (table 4).
Additionally, we estimated adjusted hazard ratios for in-
cidence of all cancer or specific cancers when we divided the
cohort by quartiles of the updated mean HbA1c values. The
25
th,5 0
th and 75
th percentiles of updated mean HbA1c were
51 mmol/mol (6.8%), 58 mmol/mol (7.5%) and 67 mmol/mol
(8.3%). This analysis showed a decreased risk of all cancer in
quartile 2, hazard ratio 0.90 (0.82–0.99), while no significant
differences in risk were seen in the highest quartiles 3 and 4, as
compared with quartile 1. No significant differences in risk for
cancer of gastrointestinal, prostate, breast or female genital
organs were found in the higher quartiles 2–4 as compared with
quartile 1 (table 5).
Table 4. Cancer incidence rate (1/1,000 person-years) and hazard ratios by quartiles of baseline HbA1c in participants with type 2
diabetes.
Quartile 1 Quartile 2 Quartile 3 Quartile 4
All cancer
No. of cases 853 874 877 829
Incidence rate per 1,000 person-years 15.71 16.18 15.69 15.36
Hazard ratio (95% CI) Reference 0.99 (0.90–1.09) 1.00 (0.91–1.11) 1.03 (0.93–1.14)
Gastrointestinal cancer
No. of cases 195 220 218 193
Incidence rate per 1000 person-years 3.24 3.66 3.52 3.23
Hazard ratio (95% CI) Reference 1.10 (0.91–1.34) 1.11 (0.91–1.36) 1.07 (0.86–1.32)
Prostate cancer
No. of cases 205 186 182 167
Incidence rate per 1000 person-years 6.17 5.70 5.97 5.00
Hazard ratio (95% CI) Reference 0.91 (0.75–1.11) 1.02 (0.83–1.26) 0.95 (0.76–1.18)
Breast cancer
No. of cases 77 75 83 74
Incidence rate per 1000 person-years 2.73 2.88 3.10 2.87
Hazard ratio (95% CI) Reference 1.02 (0.74–1.40) 1.12 (0.81–1.55) 1.02 (0.72–1.44)
Female genital cancer
No. of cases 47 45 45 46
Incidence rate per 1000 person-years 1.64 1.70 1.65 1.77
Hazard ratio (95% CI) Reference 0.99 (0.66–1.50) 0.98 (0.64–1.50) 0.99 (0.64–1.55)
Hazard ratios were adjusted for age, sex (except in sex-specific cancers), diabetes duration, smoking, and insulin treatment.
HbA1c quartile 1: ,50 mmol/mol (,6.7%); quartile 2: 50–57 mmol/mol (6.7–7.4%); quartile 3: 58–68 mmol/mol (7.5–8.4%); quartile 4: .69 mmol/mol ($8. 5%).
doi:10.1371/journal.pone.0038784.t004
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In this large-scale nationwide population-based cohort study, we
did not observe associations between higher HbA1c as a marker of
elevated blood glucose levels, i.e. poor glycemic control and
incidences of all cancers or specific types of gastrointestinal, breast
or prostate cancer, cancer in kidney and urinary organs, re-
spiratory organs or female genital organs in patients with type 2
diabetes.
The rationale for using HbA1c=58 mmol/mol (7.5%) as the
cutoff point for dichotomized comparison was that it was the
median HbA1c value. Furthermore, use of categorization by the
median HbA1c allowed for comparisons between groups with
a mean difference in HbA1c as high as 1.5–2%.
The unique features of our study is that the cohort only
consisted of patients with type 2 diabetes, and that we used HbA1c
which indicates the blood glucose level over the last 1–3 months.
Thus, our study differs from some cohorts studies which used
fasting or post-load blood glucose [18–20]. as well as from previous
studies from Sweden, Korea and Austria, which were based on
healthy survey data where the majority of cohort members were
non-diabetics [18–20]. Although these studies had large sample
size, the proportion of participants with diabetes was either
unknown [20], or only 2–5% [18,19]. The effect of fasting serum
glucose on cancer risk in diabetic participants was not reported in
these studies.
No increased or decreased risks of any cancer or specific types of
cancer were found in participants with poor blood glucose as
compared with good blood glucose control in patients with type 2
diabetes in our study. This finding is consistent with the results
from meta-analyses of major trials data of the UKPDS, the
ACCORD study and the VADT (Veterans Affairs Diabetes Trial)
study, [9] and a study with the General Practice Research
Database and secondary care data [21] also reported no
association between intensified glycemic control and cancer risk.
A recent report based on the ADVANCE study included 5,571
participants with intensive blood glucose control and 5,569 with
standard control [7]. Both groups had a mean baseline HbA1c of
58 mmol/mol (7.5%) and at the end of follow-up the intensive
control group had mean HbA1c 6.5% and the standard control
group 7.2%. After a median follow-up of 5 years, no significant
differences in any cancer risks between the two groups were
observed.
Our results are not consistent with the Hongkong study of type
2 diabetes which was based on 973 new insulin users and 971
matched non-users of insulin [22]. This study found that HbA1c
per percentage was associated with a 1.24-fold increase in cancer
risk. However, follow-up duration was quite short, the mean
follow-up being 3.01 years for insulin users and 0.70 years for
nonusers. The outcome numbers were small, with 32 cancer cases
in insulin users and 120 in non-users. Insulin users had
significantly higher HbA1c values than non-users (8.1% vs
7.1%). The authors acknowledge that HbA1c was not collected
systematically during follow-up.
Existing observational epidemiological data on associations
between blood glucose and cancer risks have shown contradictory
results, some based on healthy people or mixed groups with or
without diabetes [10,12,23–27]. Increased HbA1c values were
found to be related to an increased risk of gastric cancer in Japan,
based on a cohort among which the majority had no diabetes [23].
Table 5. Cancer incidence rate (1/1000 person-years) and hazard ratios by quartiles of updated mean HbA1c in participants with
type 2 diabetes.
Quartile 1 Quartile 2 Quartile 3 Quartile 4
All cancer
No. of cases 906 846 838 843
Incidence rate per 1000 person-years 17.03 14.97 14.87 16.17
Hazard ratio (95% CI) Reference 0.90 (0.82–0.99) 0.94 (0.85–1.04) 1.08 (0.98–1.20)
Gastrointestinal cancer
No. of cases 207 202 221 196
Incidence rate per 1000 person-years 3.49 3.21 3.58 3.39
Hazard ratio (95% CI) Reference 0.96 (0.79–1.16) 1.12 (0.92–1.36) 1.12 (0.91–1.38)
Prostate cancer
No. of cases 219 185 176 160
Incidence rate per 1000 person-years 6.99 5.47 5.24 5.15
Hazard ratio (95% CI) Reference 0.84 (0.69–1.02) 0.86 (0.70–1.06) 0.94 (0.76–1.17)
Breast cancer
No. of cases 78 72 74 85
Incidence rate per 1000 person-years 2.94 2.64 2.66 3.36
Hazard ratio (95% CI) Reference 0.88 (0.64–1.22) 0.92 (0.66–1.28) 1.15 (0.82–1.61)
Female genital cancer
No. of cases 40 50 46 47
Incidence rate per 1000 person-years 1.49 1.80 1.64 1.83
Hazard ratio (95% CI) Reference 1.17 (0.77–1.78) 1.08 (0.70–1.69) 1.18 (0.74–1.87)
Hazard ratios were adjusted for age, sex (except in sex-specific cancers), diabetes duration, smoking, and insulin treatment.
HbA1c quartile 1: ,51 mmol/mol (6.8%); quartile 2: 51–57 mmol/mol (6.8–7.4%); quartile 3: 58–66 mmol/mol (7.5–8.2%); quartile 4: .67 mmol/mol ($8.3%).
doi:10.1371/journal.pone.0038784.t005
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was reported from studies based on women in the Nurses’ Health
Study, the Women’s Health Study [10,12], in patients with type 2
diabetes [24], or in studies based on European Prospective
Investigation into Cancer and Nutrition [25,26]. Similarly, no
association between HbA1c level and risk of breast cancer was
reported in apparently healthy women in the Women’s Health
Study [28].
Diabetes has been reported to be associated with decreased risk
of prostate cancer [29]. The reason for this remains unclear.
Higher prostate-specific antigen (PSA) level is a marker of prostate
cancer. The inverse association between HbA1c and PSA was
reported in some studies [30,31] but not all [32]. Two of the
studies which found inverse associations, were cross-sectional
studies [30,31]. A two-year longitudinal study [32] of 5,917
Japanese men aged 50 and over found increased PSA with
increased HbA1c level. However, a two-year follow-up is quite
short for a cancer study.
A comparison between lower and higher quartiles of HbA1c for
all cancer or specific cancers risk was additionally performed in
this study, as quartiles of the HbA1c distribution may have higher
statistical power than dichotomization by the median HbA1c
value. A slightly decreased all cancer risk of borderline significance
when comparing updated mean HbA1c quartile 2 with the
quartile 1 could be neglected, as no effect on all cancer risk was
found in the higher quartiles 3 and 4. Furthermore, no significant
differences in risks for specific cancers were observed in quartiles
2–4 as compared with to quartile 1. Finally, analysing HbA1c
continuously per 1 per cent unit increase showed no increased risk
for all cancer or specific cancers (Table 3), as also demonstrated
with splines of 12-year incidence rates of all cancer and specific
cancers (Figure 2).
The main strengths of our study were the large sample size
based on high quality registers, the long follow-up period with
thorough follow-up, the complete information concerning baseline
HbA1c levels and cancer outcomes, and the possibility of adjusting
for relevant potential confounding factors. We could determine the
temporal sequence of the casual relationship, if any, since our
study has well documented time for HbA1c values, the diagnosis of
diabetes and the studied cancers.
Our study has some limitations. Firstly, not all patients with
diabetes in Sweden are registered in the National Diabetes
Register. However, the selection for our cohort was not related to
the study outcome – incident cancer. Thus, the risk of selection
bias is minimal. Secondly, HbA1c measurement error might be
a concern. We used both baseline and updated mean HbA1c as
markers of glycemia. HbA1c is considered a stable indicator of the
past 1–3 months’ blood glucose level. Also, the nationwide
program to calibrate HbA1c levels and guidelines of reporting
ensures high accuracy of HbA1c and reduces measurement errors.
Thirdly, the use of different diabetes medications might be related
to altered risks of incident cancer [14,33]. Since the Prescribed
Drug Register was initiated in Sweden on July 1
st 2005, we lack
information on specific diabetes medication in this study with its
baseline in 1997–1999. However, as we have information in the
NDR on whether the patients use insulin, a variable indicating
whether the patients were on insulin treatment or not at baseline
was used as a covariate in the multivariate models. Fourthly,
certain information was not available in our data at recruitment
time, such as lipid values, markers of inflammation, comorbidities,
and endogenous insulin levels. Lipid values were reported to
increase cancer risk in type 2 diabetes [34]. Since hyperglycemia
might induce abnormal lipids [35], lipids are intermediate factor in
the causal pathway between hyperglycemia and cancer. Thus,
lipids are not confounders in our study [36].
In summary, there were no significant differences in incidences
of all cancer or cancer of specific types between groups with
baseline HbA1c#58 mmol/mol (7.5%) and HbA1c.58 mmol/
mol (7.5%), or between groups with updated mean HbA1c#58 m-
mol/mol (7.5%) and HbA1c.58 mmol/mol (7.5%), in patients
with type 2 diabetes.
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